Delticom AG/My-vintage-tyres.co.uk: Ford Granada, Saab 900 or Audi 80 – the Right Tyres for Fans of Modern Classics
They represent quality, durability and a very special retro charm: the so-called “modern classics”. Strictly speaking these vehicles, between 15 and 30 years old and mostly produced in the 80s and 90s, aren’t classic cars yet, but it’s not just amongst collectors that they are growing in popularity. Whether you’re talking about sedans like the Ford Granada, cabriolets like the Saab 900 Cabrio or coupés based on the Audi 80 – all of them have already achieved cult status, with demand and value increasing accordingly. The question of how modern classics should be maintained is, however, the same as for true classic cars: true to style and in good condition, with original parts as far as possible, or at least parts which are faithful to the original. But even with retro charm, one thing shouldn’t be compromised: safety.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160922005630/en/
My-vintage-tyres.co.uk - the right tyres for fans of modern classics Picture source: Stéphane Horber
For example, tyres: as a part subject to wear, not only are tyres one of the defining characteristics of a vehicle’s appearance, they are also one of the most important safety elements - after all, they are the only component in direct contact with the road. “Many people don’t realise that tyres degrade over time, even if they don’t do a lot of mileage - which is the case for a lot of classic cars. The grip deteriorates noticeably over time, as the rubber mixture gradually hardens, meaning tyres can become porous or cracked. An eight-year-old set of tyres should be replaced under any circumstances. And of course: tyres should have a tread depth of at least 1.6 millimetres, ideally more”, says Thierry Delesalle of My-vintage-tyres.co.uk.
So the question arises: where can fans of classic cars find suitable replacement tyres? Tyre dimensions common in earlier cars are often different to those of modern models: today’s tyres, for example, are mostly larger and have a different cross-section (ratio of flank height to tread width), and your local workshop may not stock all models.
“That’s why fans of modern classics should take a look at My-vintage-tyres.co.uk“, advises Delesalle. My-vintage-tyres.co.uk is a new online shop especially for fans of classic cars and modern classics. The shop has been set up by Delticom AG, Europe’s largest online tyre retailer, meaning that buyers benefit from over 15 years’ experience in online tyre retail, perfectly rehearsed delivery logistics and expert service. “Our range includes a wide selection of historical tyre models, produced by manufacturers today in accordance with current standards”, explains Delesalle. Buyers on My-vintage-tyres.co.uk will find a range of trusted brands which meet the quality standards of enthusiasts in a range of dimensions and styles. “You can even get authentic-looking whitewall tyres”, says Delesalle. In addition to quick, intuitive online ordering, My-vintage-tyres.co.uk also offers a variety of secure payment methods and rapid delivery. If you prefer to leave the fitting to the professionals, you can also have your tyres sent to one of our fitting partners at no extra cost, where they will then be mounted on your vehicle.
Buy tyres for classic cars, modern classics and whitewall tyres at:
www.mein-oldtimer-reifen.de, www.mein-oldtimer-reifen.at, www.mein-oldtimer-reifen.ch, www.mes-pneus-collection.ch, www.mes-pneus-collection.be, www.mijn-oldtimer-banden.be, www.mijn-oldtimer-banden.nl, www.mine-gamle-dage.dk, www.mina-veterandäck.se, www.minun-vintage-renkaani.fi, www.mis-neumaticos-clasicos.es, http://www.mes-pneus-collection.fr, www.i-miei-pneumatici-depoca.it, www.meus-pneus-do-vintage.pt, www.moje-zabytkowe-opony.pl, www.my-vintage-tyres.ie, www.my-vintage-tyres.co.uk
insignis Agentur für Kommunikation GmbH (GPRA)
Anne Lena Peters
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom